A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 310
- Registration Number
- NCT04685226
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT04578613
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of ICP-192 in Patients With Advanced Solid Tumors
- Conditions
- Urothelial CarcinomaAdvanced Solid TumorsCholangiocarcinoma
- Interventions
- Drug: Drug ICP-192
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04565275
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
🇺🇸University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT04492293
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ADME Study of [14C]ICP-022 in Healthy Males
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]ICP-022
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04441450
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04440059
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Union Hospital affiliated to Fujian Medical University, Fuzhou, Fujian, China
A Study of ICP-022 in Patients With R/R DLBCL
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT04438005
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Harbin Medical University, Haerbin, Heilongjiang, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
- Conditions
- PCNSLSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT04438044
- Locations
- 🇨🇳
Capital Medical University Xuanwu Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, Beijing, China
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04305197
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University third hospital, Beijing, Beijing, China
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
- Conditions
- B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
- Interventions
- Drug: Recombinant humanized monoclonal antibody MIL62 injection
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT04304040
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China